Stablepharma and BB-NCIPD Ltd (Bul Bio) to develop a fridge-free Tetanus mono vaccine.
Stablepharma Ltd. and BB-NCIPD Ltd. (Bul Bio) have signed a second agreement for the exclusive bulk supply and commercialization of the Tetanus vaccine (SPVX06), following a similar arrangement for the Tetanus diphtheria vaccine (SPVX02) last year.
Mergermarket interviews Stablepharma on future IPO and Series B raise to launch two fridge-free vaccines
Stablepharma, a UK developer of the world’s first fridge-free vaccines, is evaluating an IPO and a financing round to bring two vaccines to market, CEO Özgür Tuncer told Mergermarket.
BIA calls on NICE to refresh evidence informing how rare disease medicines are evaluated and paid for
The UK BioIndustry Association has today published research suggesting the UK’s medicines evaluation body is basing its methods and processes for evaluating medicines for rare diseases on outdated evidence. Rare insights: examining the social values of treating rare diseases presents the findings of primary research into public opinion on how treatments for rare diseases should be evaluated and funded within the NHS.
Nonacus launches GALEAS® Bladder, a novel test for the non-invasive detection of bladder cancer
The urine-based molecular test can quickly and accurately detect bladder cancer and streamline diagnosis, thereby reducing the need for invasive cystoscopies.
Touchlight announces first FDA clearance of an IND utilising doggybone DNA
Touchlight today announced the first FDA clearance of an Investigational New Drug (IND) application in the US, utilising doggybone DNA (dbDNA). Within the clinical trial now planned by one of Touchlight’s US clients, enzymatic doggybone DNA material will be used in GMP production of a cell therapy product. This is a major landmark which demonstrates the clinical adoption of Touchlight's proprietary technology across modalities.
Achieving equity for people living with rare diseases
This year, Rare Disease Day is being celebrated on 28 February, raising awareness and working towards equity in social opportunity, healthcare, and access to diagnosis and therapies for the 300 million people worldwide living with a rare disease. In this blog, Senior Policy and Public Affairs Executive at BIA, Joe Smale, explains the difference between equality and equity and reflects on the findings of recent BIA research, indicating public support for achieving equity of access to treatments for people living with rare diseases.
Real-world evidence: the panacea for rare diseases?
The publication of the National Institute for Health and Care Excellence’s real-world evidence framework in June 2022 has accelerated discussions about the role that real-world evidence can play in resolving gaps in knowledge and driving forward access to innovations for patients with rare diseases. Senior Policy and Public Affairs Executive, Joe Smale, reflects on a recent BIA-facilitated discussion on the potential of real-world evidence in rare diseases and the importance of patient involvement in future discussions.
Industry-first cancer screening technology boosted by biomedical grant funding
Medicines Discovery Catapult and SMi secure funding to validate cancer biomarker technology
Touchlight and Odimma Therapeutics announce clinical material supply agreement to develop personalised cancer therapy
Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announces a development and supply agreement with Odimma Therapeutics, a French biotech company focusing on personalised cancer immunotherapy.
IBD Market Snapshot: New Medicines Try To Address Patient, Physician Demands - Oral Drugs, Novel Biologics Offer New Options
Remission rates with existing therapies leave much room for improvement, so a variety of treatments are needed – leaving major players attempting to carve unique paths in a crowded market.